Intellectual Product – Page 2

Uncertainty Clouds Finances for Payers and Health Systems in Q2 2025

2 weeks ago talkbio0Tagged Budgets, Changing, Consumer, federal, health systems, healthcare financial performance, Hospital admission, Medicaid, Medicare, payers, Policy, Q2 2025, Uncertainty

Q2 2025; healthcare financial performance; payers; health systems; uncertainty; Medicaid; Medicare; admissions; policy changes; federal budget; consumer confidence

Obesity Leaders Dig Manufacturing Moats To Defend Injectable GLP-1 Empires

2 weeks ago talkbio0Tagged Bariatric Surgery, biosimilars/generics, Capital Expenditures, China, competition, constraints, eli lilly, GLP-1 pipeline, Glucagon-Like Peptide 1, manufacturing capacity, Market, Medicare, Nordisk, Obesity, Policy, Risk, Wegovy, Zepbound

GLP-1; manufacturing capacity; Eli Lilly; Novo Nordisk; obesity drugs; Wegovy; Zepbound; capital expenditures; supply constraints; market competition; Medicare coverage; policy risk; biosimilars/generics; China GLP-1 pipeline; bariatric surgery

Boehringer Ingelheim breaks into oncology as FDA grants accelerated approval to Hernexeos (zongertinib) for HER2 TKD–mutated NSCLC

2 weeks ago talkbio0Tagged Accelerated, Approved, Beamion, Boehringer Ingelheim, competition, Confirmatory Trial, Enhertu, erbB-2 Receptor, Frequency of Responses, HER2-mutant, Hernexeos, Identifier, LUNG-1, Mutation, Non-Small Cell Lung Carcinoma, non-squamous NSCLC, Oncomine Dx Target Test, oral targeted therapy, Priority Review, Requirement, TKD, United States Food and Drug Administration, Zongertinib

Boehringer Ingelheim; Hernexeos; zongertinib; FDA approval; accelerated approval; non-squamous NSCLC; HER2 TKD mutations; Oncomine Dx Target Test; Beamion LUNG-1; objective response rate; first oral targeted therapy for HER2-mutant NSCLC; priority review; breakthrough therapy designation; confirmatory trial requirement; competition with Enhertu

AI, Media and the Evolution of Omnichannel in Healthcare Marketing — Ray Rosti on Episode 3 of The Next Marketing with HJ

2 weeks ago talkbio0Tagged Aortic Valve Insufficiency, Automation, Biomechanical compliance, Communications Media, connected journeys, content intelligence, Doceree, Engaged to be married, Health Care Market, Hereditary Coproporphyria, Klick Media, Measurement, omnichannel, Optimization, personalization, Pharma, Privacy, Region of interest:Presence or Identity:Point in time:*:Nominal

AI in healthcare marketing; omnichannel; first‑party data; content intelligence; media optimization; privacy and compliance; measurement and ROI; pharma marketing; Klick Media; Doceree; HCP engagement; personalization; automation; connected journeys

HHS ousts MAHA implementation lead amid rushed cancellations of $500M in mRNA vaccine contracts

2 weeks ago talkbio0Tagged BARDA, CHARGE Syndrome, Contract agreement, Gray Delany, MAHA, Moderna, mRNA contracts, Pfizer, Policy, Robert F. Kennedy, Seqirus, Shakeup, SMPX gene, Staff, terminations, Vaccines

HHS; MAHA; Gray Delany; mRNA contracts; BARDA; Robert F. Kennedy Jr.; vaccine policy; contract terminations; Moderna; Pfizer; CSL Seqirus; staff shakeup

Amid MFN Talks, Lilly Chief Warns US Adoption of International Drug Prices Could Bring ‘Worst of Two Worlds’

2 weeks ago talkbio0Tagged Cautionary Warning, Chief, Does speak, Drug Industry, drug price, Eli Lilly, International Drug Prices, MFN, Policy, U.S.

Lilly chief; MFN talks; international drug prices; US drug pricing; pharmaceutical industry; policy warning

Trump Announces Massive Pharma Tariffs Up to 250%, Signals Enforcement Within Days

3 weeks ago talkbio0Tagged Biopharma, Canada, fentanyl crisis, international trade, Pharma Tariffs, Sectioning technique, tariff increase, Transplant Registry Unified Management Program

Trump; pharma tariffs; tariff increase; biopharma; Canada; Section 301; international trade; fentanyl crisis

AstraZeneca Expands AI Collaboration with SOPHiA GENETICS for Breast Cancer Research

3 weeks ago talkbio0Tagged AI Factories, AstraZeneca, Clinical Data, Genomics, Malignant neoplasm of breast, predictive models, real-world evidence, SOPHiA GENETICS

AstraZeneca; SOPHiA GENETICS; AI Factories; breast cancer; predictive models; real-world evidence; genomics; clinical data

Pfizer CEO Holds ‘Extremely Productive’ Talks With Trump Administration Amid MFN Pricing and Tariff Threats

3 weeks ago talkbio0Tagged Albert Bourla, Direct-to-Consumer, Drug Industry, drug price, Jr., Mehmet, Nation, negotiation, ounce, Pfizer, PhRMA, Policy, Pricing, Robert F. Kennedy, tariffs, Trump administration

Pfizer; Albert Bourla; Trump administration; Most Favored Nation (MFN) pricing; drug pricing; tariffs; pharmaceutical industry; direct-to-consumer (DTC) sales; policy negotiation; Robert F. Kennedy Jr.; Mehmet Oz; PhRMA

BioMarin Drops Preclinical PKU Drug Once Seen as Potential Palynziq Successor

3 weeks ago talkbio0Tagged BioMarin, Drug Development, Immunogenicity (package insert), Palynziq, Phenylketonurias, R&D pipeline

BioMarin; PKU; Palynziq; BMN 390; drug development; R&D pipeline; immunogenicity